Exai Bio is a startup based in the United States, most recent round Series A, 1 tracked investor.
Exai Bio is a company headquartered in the United States. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Exai Bio is a next-generation liquid biopsy company that utilizes RNA biomarkers and artificial intelligence to deliver clinical insights into cancer biology, enabling early and accurate cancer detection through non-invasive blood tests.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.